Cargando…

Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma

AIM: Merkel cell carcinoma (MCC) is a rare neuroendocrine, cutaneous malignancy with poor prognosis once metastasized. The aim of this study was to conduct a systematic literature review to assess clinical outcomes associated with chemotherapy regimens in metastatic MCC. >MATERIALS & METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nghiem, Paul, Kaufman, Howard L, Bharmal, Murtuza, Mahnke, Lisa, Phatak, Hemant, Becker, Jürgen C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2017
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040046/ https://www.ncbi.nlm.nih.gov/pubmed/28350180 http://dx.doi.org/10.2217/fon-2017-0072

Ejemplares similares

Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US
por: Bharmal, Murtuza, et al.
Publicado: (2019)

Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
por: Lanitis, Tereza, et al.
Publicado: (2019)

Living with Merkel Cell Carcinoma (MCC): Development of a Conceptual Model of MCC Based on Patient Experiences
por: Kaufman, Howard L., et al.
Publicado: (2018)

Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe
por: Becker, Jürgen C., et al.
Publicado: (2017)

Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma
por: Bharmal, Murtuza, et al.
Publicado: (2017)

Correction to: Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma
por: Bharmal, Murtuza, et al.
Publicado: (2019)

Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
por: Bullement, Ash, et al.
Publicado: (2019)

Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study
por: Bhatia, Shailender, et al.
Publicado: (2022)

Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives
por: Kongnakorn, Thitima, et al.
Publicado: (2019)

Travel burden associated with rare cancers: The example of Merkel cell carcinoma
por: Jain, Rahul, et al.
Publicado: (2019)

Update on the psychometric properties and minimal important difference (MID) thresholds of the FACT-M questionnaire for use in treatment-naïve and previously treated patients with metastatic Merkel cell carcinoma
por: Bharmal, Murtuza, et al.
Publicado: (2020)

Treatment Patterns, Overall Survival, and Total Healthcare Costs of Advanced Merkel Cell Carcinoma in the USA
por: Steuten, Lotte, et al.
Publicado: (2019)

Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma
por: D’Angelo, Sandra P., et al.
Publicado: (2019)

Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial
por: Lambert, Jérémy, et al.
Publicado: (2020)

Clinical Outcomes, Costs, and Healthcare Resource Utilization in Patients with Metastatic Merkel Cell Carcinoma Treated with Immune Checkpoint Inhibitors vs Chemotherapy
por: Zheng, Ying, et al.
Publicado: (2021)

Treatment Sequencing Patterns in Patients with Metastatic Urothelial Cancer Treated in the Community Practice Setting in the United States: SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR)
por: Doshi, Gurjyot K, et al.
Publicado: (2020)

Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma
por: Iyer, Jayasri G., et al.
Publicado: (2016)

How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial
por: Bharmal, Murtuza, et al.
Publicado: (2018)

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
por: Kaufman, Howard L., et al.
Publicado: (2018)

Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab
por: Bharmal, Murtuza, et al.
Publicado: (2020)

Complete Spontaneous Regression of Merkel Cell Carcinoma Metastatic to the Liver: Did Lifestyle Modifications and Dietary Supplements Play a Role?
por: Vandeven, Natalie, et al.
Publicado: (2012)

Association of Merkel Cell Polyomavirus–Specific Antibodies With Merkel Cell Carcinoma
por: Carter, Joseph J., et al.
Publicado: (2009)

Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
por: Zaremba, Anne, et al.
Publicado: (2019)

Single-fraction radiation therapy in patients with metastatic Merkel cell carcinoma
por: Iyer, Jayasri G, et al.
Publicado: (2015)

Management and Prognosis of Cardiac Metastatic Merkel Cell Carcinoma: A Case–Control Study and Literature Review
por: Akaike, Tomoko, et al.
Publicado: (2022)

P29. T-cell responses to oncogenic Merkel cell polyomavirus proteins distinguish Merkel cell carcinoma patients from healthy donors
por: Lyngaa, L, et al.
Publicado: (2014)

Radiotherapy for Metastatic Merkel Cell Carcinoma: A Review of the Literature
por: Khan, Luluel, et al.
Publicado: (2012)

Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma
por: Ritter, Cathrin, et al.
Publicado: (2016)

Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma
por: Ritter, Cathrin, et al.
Publicado: (2017)

Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up
por: D'Angelo, S.P., et al.
Publicado: (2021)

Clinical Benefit from Tyrosine Kinase Inhibitors in Metastatic Merkel Cell Carcinoma: A Case Series of 5 Patients
por: Tarabadkar, Erica S., et al.
Publicado: (2018)

Highly Expressed miR-375 is not an Intracellular Oncogene in Merkel Cell Polyomavirus-Associated Merkel Cell Carcinoma
por: Fan, Kaiji, et al.
Publicado: (2020)

Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
por: da Silva, Wânia Cristina, et al.
Publicado: (2018)

First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study
por: D'Angelo, Sandra P, et al.
Publicado: (2021)

Metastatic Merkel cell carcinoma response to nivolumab
por: Walocko, Frances M., et al.
Publicado: (2016)

Is this the end of cytotoxic chemotherapy in Merkel cell carcinoma?
por: Rabinowits, Guilherme
Publicado: (2017)

Does a new polyomavirus contribute to Merkel cell carcinoma?
por: Garneski, Kelly M, et al.
Publicado: (2008)

Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy
por: Miller, Natalie J., et al.
Publicado: (2018)

Effect of Intravenous Chemotherapy Regimen on Globe Salvage Success Rates for Retinoblastoma Based on Disease Class—A Meta-Analysis
por: Daniels, Anthony B., et al.
Publicado: (2021)

Discovery of CD8 T cell epitopes in Merkel cell polyomavirus through combinatorial encoding with MHC multimers
por: Lyngaa, Rikke, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_kkmpp6ui9cpb9il78a9crkovns